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Introduction
According to Stanley B. Prusiner, prions belong to an
unprecedented class of infectious agents  because they are
devoid of nucleic acid, and seem to be composed exclusively
of a modified mammalian protein [18, 38].
Prion-due diseases are usually lethal and are commonly
termed transmissible subacute spongiform encephalopathies
(TSE) owing to the sponge-like aspect of the brains of infected
individuals brought about by extensive vacuolation in brain
tissues. Among the best known TSE are sheep scrapie and bovine
spongiform encephalopathy (BSE), in animals, and Creutzfeldt-
Jacob disease (CJD), in humans [36] (Table 1).
Until now, most cases of CJD have occurred sporadically
(only one case per 1 million individuals per year). About 10%
of cases are considered to be of genetic origin. The inherited
form has been detected in about one hundred  families. Also,
all cases of CJD initially described as being of infectious origin
are iatrogenic. Following the crisis of mad cow disease, it is
believed that bovine prions, responsible for BSE, may have
been passed to humans resulting in a new form of CJD or variant
CJD (vCJD). Both in these and in other TSE, the common
feature is the accumulation of the modified form of a normal
cell protein in affected brains [38].
On investigating sheep scrapie, Prusiner isolated a purified
extract of the infectious agent. Seeing that it resisted inactivation
by procedures that modify nucleic acids, he concluded that he
was essentially dealing with a hydrophobic protein and therefore
termed it Prion (proteinaceous infectious particle) [35]. The
scrapie agent contains a principal protein, the so-called prion
protein (PrP) [36].
Later, it was discovered that prion protein is host encoded. In
humans, PrP is encoded by the PrnP gene. Thus, this gene—
which has been identified in all mammals studied and which is
highly conserved—encodes a normal cellular protein of unknown
function. PrP occurs in two different forms; the normal cellular
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Prions: an evolutionary perspective
Summary Studies in both prion-due diseases in mammals and some non-Mendelian
hereditary processes in yeasts have demonstrated that certain proteins are able to trans-
mit structural information and self-replication. This induces the corresponding confor-
mational changes in other proteins with identical or similar sequences. This ability of
proteins may have been very useful during prebiotic chemical evolution, prior to the
establishment of the genetic code. During this stage, proteins (proteinoids) must have
molded and selected their structural folding units through direct interaction with the
environment. The proteinoids that acquired the ability to propagate their conformations
(which we refer to as conformons) would have acted as reservoirs and transmitters of a
given structural information and hence could have acted as selectors for conformatio-
nal changes. Despite the great advantage that arose from the establishment of the gene-
tic code, the ability to propagate conformational changes did not necessarily disappear.
Depending on the degree of involvement of this capacity in biological evolution, we
propose two not mutually exclusive hypotheses: (i) extant prions could be an atavism
of ancestral conformons, which would have co-evolved with cells, and (ii) the evolution
of conformons would have produced cellular proteins, able to transmit structural infor-
mation, and, in some cases, participating in certain processes of regulation and epige-
nesis. Therefore, prions could also be seen as conformons of a conventional infectious
agent (or one that co-evolved with it independently) that, after a longer or shorter adap-
tive period, would have interacted with conformons from the host cells.
Key words Prion · Conformon · Protein evolution · Conformational change ·
“Yeast prions”
scrapie) or PrPres (from protease-resistant). PrPC and PrPSC have
the same amino acid sequence but differ in their three-dimensional
conformations. They are therefore conformational isomers [36].
Table 1 The prion diseases [see Ref. 38]
Disease Mechanism of pathogenesis
Human diseases
Kuru (Fore people, Papua New Guinea) Infection through ritualistic
cannibalism
Iatrogenic Creutzfeldt-Jakob disease Infection from prion-contaminated 
HGH,* dura mater grafts, 
and so forth
Variant Creutzfeldt-Jakob disease Infection from bovine prions?
Familial Creutzfeldt-Jakob disease Germline mutations in PrP gene
Gerstmann-Sträussler-Scheinker disease Germline mutations in PrP gene
Fatal familial insomnia Germline mutations in PrP gene 
(D178N and M129)
Sporadic Creutzfeldt-Jakob disease Somatic mutation or spontaneus 
conversion of PrPc into PrPsc (?)
Animal diseases
Scrapie (sheep) Infection in genetically susceptible
sheep
Bovine spongiform encephalopathy (cattle) Infection with prion-contamined
MBM**
Transmissible mink encephalopathy (mink) Infection with prions from sheep or
cattle
Chronic wasting disease (mule deer, elk) Unknown
Feline spongiform encephalopaty (cats) Infection with prion-contaminated
MBM
Exotic ungulate encephalopaty Infection with prion-contaminated
(greater kudu, nyala, oryx) MBM
* HGH: Human Growth Hormone.
** MBM: Meat and Bone Meal.
According to the protein-only hypothesis, PrPC undergoes a
conformational change, induced by direct interaction with PrPSC
(transient formation of a heterodimer) and is then converted into
PrPSC. In turn, this infectious form of PrP is able to propagate
its new conformation to other PrPC molecules. PrPC contains much
more α-helix than β strand, i.e. 42% α versus 3% β strand. The
conformational change, involves the stretching of some portion
of these helixes and their conversion into β strands. However,
PrPSC preserves a large part of α helix (30% versus 43% β strand)
[9, 31]. These results suggest that at least a large part of the 
β pleated sheet domains are originated from the amino-terminal
region of PrPC, which is less structured [40, 41]. Recently, it
has been reported that this region undergoes a profound
conformational change located at residues 90 to 112, during the
transformation of PrPC into PrPSC [34].
This structural modification is accompanied by significant
differences in the chemical properties of both isoforms; unlike
the cellular form, PrPSC is not soluble in non-denaturing
detergents and it also displays a certain degree of resistance
to protease digestion, which is not seen in PrPC [36]. Other
experiments, whose results support the protein-only hypothesis,
seem to prove the in vitro conversion of PrPC mediated by PrPSC,
although the resulting material is not infectious [2].
As well as the foregoing, the protein-only hypothesis—
which is currently favoured by most researchers in the field—
receives support from other observations, mainly genetic.
Knock-out (KO) transgenic mice, which do not express the
PrP gene, are viable [4]. In fact, despite its ubiquitous
localization—mainly in the brain, but also in other organs—
the function of PrPC is unknown. Nevertheless, the gene
encoding PrPC has been found to be an essential component
for the development of all pathological forms. In humans,
non-conservative mutations in the PrP gene have been
detected in all hereditary forms of TSE [38]. Prusiner believes
that prions may be generated de novo through mutations in
PrP. Thus, in experiments conducted on transgenic mice,
in which a mutated gene of PrP had been introduced, this
gene was seen to govern the period of incubation of the
disease; the greater the number of copies, the earlier the onset
of the disease [4, 19, 20, 45, 46]. In these experiments, it was
observed that the molecules of mutant PrP were able to adopt
the infectious conformation since (i) transgenic mice that
produce large amounts of mutant PrP developed all the
symptoms of the disease, and (ii) inoculation of brain tissue
from mice suffering from TSE to healthy mice, which
produce the same mutant PrP, at low level, transferred the
disease to the latter animals. In turn, the brain tissue of these
latter was able to propagate the disease to other identical
healthy mice. It would seem that the requirement of the PrP
gene for the disease to appear and the nature of modified PrP
as a transmissible infectious agent have been demonstrated.
In this sense, KO mice were found to be resistant to infection
with prions.
The species barrier is not identical for all species.
Essentially, it depends on the greater or lesser identity in the
amino acid sequence of the PrP of the species (donor and
receptor) considered (above all that of certain regions of the
protein) [37, 39]. Transgenic mice that express the PrP gene
from the Syrian hamster may develop the disease when they
receive hamster prions while normal mice do not [43]. Thus
the greater the similarity in the PrP, prion and cellular
sequences of the host, the greater the probability of disease
transmission. Furthermore, other factors also contribute to
the species barrier; namely, the strain of the prion and the
species specificity of the so-called protein X [38]. Infectious
material from different sources can produce distinct and
reproducible patterns of incubation times, distribution of
Central Nervous System (CNS) involvement and even the
patterns of proteolytic cleavage of PrPSC. The concept of prion
“strains” lies on such differences of the same converted PrPC
(reviewed in [18]). For Prusiner, each prion strain seems to
be identified by a given conformation of the many
conformations that a PrPSC species may adopt (identified
by their sequence) [46]. These conformations propagate by
inducing the corresponding conformational change in PrPC
with appropriate sequences (that is, that they do not display
differences that might act as a “species barrier”). Protein X
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has been proposed to act as a molecular chaperone, binding
to the terminal COOH region of the PrPC, of its same species,
and facilitating its conversion into PrPSC [22, 45].
As well as the species barrier, other phenomena suggest a
certain degree of variability among prions and also the existence
of different strains. As mentioned, Prusiner explains this
variability by assuming that PrPC are able to adopt different
conformations [2, 5, 30]. The preservation of in vitro strain
specificity has been reported [2]. In this sense, it has been
observed that a given PrPC, incubated with different strains of
prions, develops into the PrPSC strain corresponding to the strain
used as template. Thus, new strains of prions may also be
generated during the passage of a given PrPSC through animals
with different PrP genes [44].
Prions and prebiotic evolution
The capacity shown by prions to propagate their protein
conformation may have been very useful during the stage of
chemical evolution prior to the appearance of life.
Crystallographic studies of the structure of the proteins
suggest that they only use a low number of folding
conformations. This limited number of tertiary structures is,
however, much higher than the number of secondary and
supersecondary structures [8].
By contrast, enormous diversity is seen on analyzing the
sequences of the proteins. Despite this, examination of the
patterns of variability of different protein families reveals
strong structural constraints on such variability [3]. These
restrictions mainly affect hydrophobic residues (which
essentially form the hydrophobic core of the proteins), which
therefore contribute most of the structural information.
Conversely, the variability seen in the polar residues of the
surface of the proteins is generally much greater. In this sense,
there is considerable evidence to suggest that the gene
segments (exons) on which the mechanisms of diversity
generation act basically correspond to the protein structural
units selected along evolution [14].
In our opinion, all these data about the structure of the
proteins suggest that they may have evolved in two main stages:
(i) an initial, prebiotic, conformational evolutionary stage, in
which a small number of conformations was selected from
randomly-formed polypeptide sequences (probably all possible
conformations, which are those currently found in all proteins);
and (ii) a second stage of sequential evolution, in which—from
already genetically encoded polypeptides, and using the
mechanisms of diversity generation developed along biological
evolution—enormous variability in the protein sequences
became accumulated, although always conserving the
conformation selected during the previous step.
During the long prebiotic stage of chemical evolution, the
structure of the proteins (proteinoids) must have become conformed
and selected through direct interaction with the environment. After
the establishment of the genetic code (origin of the first cells
and the beginning of evolution through natural selection), all the
adaptive modifications of the proteins (i.e. the structural units
selected during the prebiotic stage) occurred through the “new
pathway” which, paradoxically, implied both stability and
conservation as a source of variability DNA !RNA !Proteins.
In this sense, we believe that during the transition from prebiotic
to biological evolution through natural selection the environment
may have changed from having a direct instructive role to a
fundamentally selective role for the genetically encoded protein
variability.
Throughout the prebiotic stage, some ability to propagate
protein conformations, similar to that currently displayed by
prions, may have been fundamental in order to advance
towards biological evolution (establishment of the genetic
code). From an evolutionary point of view, proteinoids that
acquired this ability (as it will be explained later, we propose
the terms “conformers” or “conformons” to refer to them)
would have been protein structures that were essentially
selected for their ability to induce conformational changes,
depending on their structure and function (propagation
capacity), in certain polypeptides that showed sequences
compatible with the change. They would therefore have acted
as selectors for favourable changes (permissive changes in
specificity with the essential structural units), facilitating
their propagation. In other words, of all the polypeptides—
formed randomly in the “primeval soup” and compatible with
the capacity to propagate their conformations—shown by
conformons, those bearing the most suitable active sites to
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Fig. 1 Conformons and prebiotic evolution. During the prebiotic stage,
proteinoids with the capacity to propagate their conformations (like current
prions) would have been selected by: (i) their structural stability and their
capacity for structural propagation, and (ii) some somewhat non-specific
enzymatic capacity (sensu latu). As far as our knowledge about the species
barrier phenomenon goes, the newly formed conformon would be able to select
other proteinoids more similar to it rather than the previous one, implying the
beginning of a new line in evolutionary progression
carry out increasingly more specific activities would have
been positively selected. However, although efficient and
lasting, in this function they would not have had rapid and
precise genetic mechanisms of inheritance for the transference
of these finely-tuned changes (Fig. 1). In this stage—in the
prebiosphere—these more efficient protein structures would
have accumulated and associated, forming protobionts with
elementary metabolism and reproductive capacity.
Prions and cellular evolution: 
the case of yeast
Despite the enormous evolutionary advantage implied by the
appearance of a genetic code, the property of the induction of
conformational changes did not necessarily have to disappear.
Here we propose two possible theoretical frameworks, which
are not necessarily mutually exclusive, that depend on the degree
of participation of prions/conformons in biological evolution:
(i) prions as an evolutionary atavism of ancestral conformons
that, as independent entities, would have coevolved with cells,
and (ii) conformons as cellular proteins that would have
participated in certain regulatory and epigenetic processes. As
indicated above, this second possibility does not exclude the
possible existence of prions as relatively independent entities.
In the first case, therefore, prions could be an atavism from
the prebiotic stage that, owing to their peculiar characteristics,
would have persisted up to the present, propagating their structure
through conformational changes in certain genetically
synthesized proteins. The biological evolution of cells would
have been accompanied by the coevolution of a kind of
“germinal” prion line that would have operated across the
generations on proteins that changed genetically. Prions would
have propagated their conformations, but not their sequences,
in proteins with sequences compatible with such conformations.
Thus, prions would have established a conformational line whose
sequences would have varied with cellular evolution (Fig. 2).
As we have seen, certain strains of prion induce certain
conformational changes in some sequences rather than in others.
A given form of prion can propagate as such in a given PrPC with
an appropriate sequence for such propagation, while in another
PrPC it would induce a different form. As prions (as independent
entities) infected different cell types along the course of evolution,
new prion species may have become selected, defined by the
amino acid sequence of the cellular protein that was most suitable
for the transformation. The species barrier would only appear in
PrPC sequences incompatible with the conformational change.
Generally, this barrier would become stronger as the species
diverge in evolutionary terms. However, it would always be
possible to find “bridge” species between two species showing
the barrier effect (Fig. 3). As discussed below, if there were prions
in bacteria, the probabilities of bridging the barrier among species,
by horizontal transmission mechanisms, would increase
considerably.
The second theoretical scenario finds support in the adaptive
fitness of prion-like molecular mechanisms in lower eukaryotes.
Since 1994 much evidence has been gathered in favour of the
existence of physiological molecular mechanisms in yeasts and
in the fungus Podospora anserina that would imply the
propagation of conformational changes in proteins, similar to
what has been proposed in the protein-only hypothesis for prion
replication [11, 49, 50]. In this sense, according to S. Lindquist
“yeast prions” would behave as inheritable  genetic elements.
Thus, “in both mammalian and yeast prions, protein structure
acts in a manner previously thought to be the unique province
of nucleic acids, in the one case as transmissible agents of disease,
and in the other as heritable determinants of phenotype” [27].
In the yeast Saccharomyces cerevisiae there are two
phenotypes, [PSI+] and [URE3], that are dominant and
inherited in a non-Mendelian manner. In the [PSI+] phenotype,
the chromosomically encoded protein Sup35 (a subunit of the
translation termination factor) may accumulate in a non-
functional aggregate through a process similar to that of prions.
This process produces the suppression of nonsense codons
which, if this did not occur, would be lethal. Likewise, in the
[URE3] phenotype, the Ure2 protein can exist in an inactive
aggregated form. Under certain environmental conditions, this
form may provide a certain selective advantage to the [URE3]
phenotype [6, 12, 28, 32, 49]. Among other interesting
observations, in these latter studies it was observed that Sup35
and Ure2 do not have homologous sequences; however, whereas
their normal biological functions are located in their carboxy-
terminal domains, the amino-terminal domains are dispensable
and have an unusual amino acid composition. Likewise,
deleting the amino terminus suppresses these phenotypes. By
contrast, over-expression of Sup35 or Ure2 (or of their
NH2–terminal domains) may induce the non-Mendelian
elements de novo.
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Fig. 2 Coevolution of a prion conformational line throughout cellular evolution.
Parallel to cellular evolution, a coevolution of prions would have occurred, in
which positively-selected conformations would have been propagated and
modified by the most suitable cellular proteins of the host cell (PrPC)
As happens with mammalian prions, in yeasts it is assumed
that the amino-terminal domains of these proteins undergo
aggregation-dependent structural alterations that somehow
affect the corresponding functional domains. The N-terminal
domain of Sup35 or Ure2 acquires an altered conformation that
can interact with other molecules of the same type, causing
them to adopt the same form. 
Another similarity with mammalian prions lies in the
involvement of a chaperone (the proposed protein X) in yeasts.
Thus chaperone HSP104 (heat-shock protein 104) plays an
essential role in the inheritance of the [PSI+] phenotype;
maintenance of this phenotype requires an intermediate
concentration of HSP104 and the phenotype may be lost through
both an excess and a deficit in HSP104 [6, 32].
Continuing with the similarities with mammals, Sup35 is
more resistant to digestion in cells having the [PSI+] phenotype
and Ure2 is more resistant in cells with the [URE3] phenotype
[28, 32]. Similarly, Sup35 is found in the form of large
aggregates in [PSI+] cells but is soluble in cells with the [psi–]
phenotype. Direct visualization of the conversion process with
GFP (green fluorescent protein) shows that when cells contain
aggregates, these are transmitted to the daughter cells [32].
Differences in [PSI+] phenotypes attributable to different
conformational variants of Sup35 have been detected. This
phenomenon would also be similar to that of prion strains in
mammals [12].
Thus, the two “protein only” phenomena—where apparently
mammalian PrP acts like a virus, and yeast Sup35 acts like a
gene—may share a common mechanism involving a nucleation-
or seed-dependent polymerization process [16, 25]. In this
sense, in vitro both Sup35 and its amino-terminal domains form
amyloid fibrils through a nucleated polymerization mechanism
[15, 23, 33]. Likewise, cytoplasm derived from PSI+ cells is
able to induce the conversion of 400-fold excess of the normal
monomeric form of Sup35 [33].
For Lindquist, the [PSI+] and [URE3] phenotypes help yeast
populations to respond rapidly to changes in their environment:
in [PSI+] strains, the pattern of gene expression may be altered.
It is possible that [PSI+] could afford a mechanism through which
individuals with identical genomes are able to adapt to different
selective niches. Rather than a mechanism of environmental
adaptation, [PSI+] would represent a mechanism for accumulating
genetic variants that are suppressible under certain natural
conditions. Finally, since [PSI+] is regulated by HSP104, and
since HSP104 is induced by environmental stress, this
phenomenon affords the first plausible molecular mechanism for
a cell to respond to its environment with an inheritable
phenotypical change. For Lindquist, [PSI+] and [URE3] offer a
convincing argument that phenotypical inheritance may sometimes
be based on the inheritance of different conformations of proteins
rather than on the inheritance of nucleic acids [27].
In view of the physiological role of both the change and
propagation of the conformations of these proteins in healthy
cells, we believe it is appropriate to use an unequivocal term
for the proteins that, using these mechanisms, do not have an
infectious role: (i) in their possible prebiotic origin, (ii) in their
cellular evolution, and (iii) in their physiology. We thus propose
the term conformon to refer to the cellular protein agent able
to propagate one of the possible conformations (through direct
contact) in other proteins compatible with such changes. The
protein undergoing this conformational change may be a
different conformation of the same protein or another closely
related one, in both structural and functional terms, within the
framework of a physiological response. A prion (infectious
protein particle) would be a conformon of a conventional
infectious agent (or one that evolves in it) that would interact
with the conformons of the host.
Some obscure points
Within the set of PrP transformed into the pathological form
the ratio of infectious units to protease-resistant molecules is about
1:100,000 or less. This fact suggests that the infectious units would
be a smaller and different fraction of a mixture of different PrP
[51]. Currently, it is unknown whether the in vitro “conversion”
of PrPC gives rise to infectivity and not only to a protease-resistant
isoform [2]. “Interestingly, pretreatment of PrPSC with 3 M
guanidine HCl, which produces a reversible unfolding of PrPSC,
increases the extent of conversion, suggesting that PrPSC itself
may also need to undergo a conformational change for conversion
to proceed, potentially accounting for the high particle:infectivity
ratio” [18]. However, it is known that  prion-due diseases may
occur in the absence of detectable levels of PrPres [10]. Non-
infectious PrPres may also be generated [42].
In view of this, Weismann has adopted a different terminology
from that of Prusiner to refer to prions. Weismann used the term
PrP* for the infectious form, which “may coincide or not with
the protease-resistant form PrPres, or PrPSC” [1, 47, 48].
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Fig. 3 Species barrier and bridge prions. Bridge species would have intermediate
sequences between two species (here A and B) showing the barrier effect.
Species A1 would have a sequence very similar to that of species A but would
be closer to B than A. Species A2 would be very similar to A1 but would be
closer than it to B. The same follows for B1, B2, etc. In this figure, A4 is
identical to B4. Thus, the prions could propagate from A to B by conformational
changes through bridge species
Other authors, who favour the viral hypothesis (they propose
that the agent of TSE would be an unusual virus), distinguish
between PrPres and infectivity [26]. In a study of the interspecies
transmission of BSE to mice, although all mice injected showed
neurological symptoms and neuronal death, it was observed
that PrPres could not be detected in more than 55%. During serial
passages, PrPres appeared (together with neuronal vacuolation
and astrocytosis) after the agent had become adapted to its new
host. These authors suggested that PrPres could be involved in
species adaptation but that another unidentified agent  able to
transmit BSE must exist. Despite this, currently very little is
known about how brain damage occurs in TSE and it would
be unwise to draw hasty conclusions. Nevertheless, there is
evidence to suggest that neuronal death could be due to a deficit
in PrPC rather than to the production of PrPSC [1, 18].
Additionally, those favouring the viral hypothesis find
another weak point in the conformational hypothesis advanced
by Prusiner to explain the polymorphism of prions. They base
their argument on the difficulty for a single protein to adopt a
large variety of different conformations, and are rather inclined
to the notion of different strains of another transmissible agent,
perhaps a rare virus [7, 13, 26]. Other authors have also doubted
the exclusively genetic interpretation of certain types of TSE
and propose the existence of an infectious agent: “Scrapie is
not solely a genetic disease, as scrapie-associated PrP alleles
are present in sheep from Australia and New Zealand, both
countries that are entirely free of scrapie” [21].
We believe that one could be dealing with ancestral
conformons/prions and/or cellular conformons/prions that, by
“riding” conventional infectious agents, have hopped from one
species to another throughout evolution. These agents would
mainly be cellular, although the possibility of some virus bearing
prions, or the gene of a prion, cannot be ruled out. In any case,
the prion would act as postulated in the protein-only hypothesis.
The polymorphism would be difficult to detect since sequence
differences would only appear in infecting prions (which could
be low in number). These sequence differences would correspond
to greater or lesser conformational differences. Each of the
different possible conformations could propagate on the unique
substrate of the PrPC of infected cells. In this way, a single PrPC
sequence could adopt several different conformations, induced
by the different conformations of the infecting prions. In this
case, one would be confronting a high number of PrP with
identical sequences and different conformations together with
a lower number of exogenous infectious PrP (PrP*, in the
terminology of Weismann) (Fig. 4).
As we have seen, these PrP* may arise from bacteria or
other infectious organisms. Bacteria are able to act very well
as “bridge species” owing to their greater probability of
mutation, the capacity for horizontal genetic transmission and
their ability to incorporate human genes [17]. If the adaptation
involved modification capacity, in bacteria, prions would be
able to considerably increase their variability in a way similar
to that shown in Fig. 2. At the same time, bacteria can acquire
PrP genes from mammals (including humans), which could
also generate new mutant prions. These mutants would be
selected by the PrPC of the host; those overcoming the species
barrier would be selected positively and those unable to
overcome it would be selected negatively. In support of the
possible involvement of bacteria or other conventional infectious
agents, in prion-due diseases it has been reported that the
antibiotic amphotericin B can retard both the clinical symptoms
and the appearance of protease-resistant PrP (PrPres) aggregates
in diseased brain tissue, without affecting the levels of the agent
replication [51]. Despite the role that we propose for
conventional infectious agents in TSE, in certain cases of
experimental, iatrogenic or alimentary infections, infection due
to prions alone cannot be ruled out. In any case, owing to the
low frequency of natural cases, the infection process must be
long and complex. In infection, apart from the amount and
diversity of PrP*, the following may also vary: the route of
entry, the amount of PrPC produced by the host’s cells, the
greater or lesser similarity between the infectious strains and
the cellular isoform, the presence of possible vectors harbouring
the prion strains (bacteria, protozoa, fungi, etc.), the presence
of other proteins that influence pathogenesis (chaperones), etc.
In this sense, it is interesting that differentiated B lymphocytes
play an important role in prion neuroinvasion, perhaps by acting
as physical carriers of the prions [24]. In our opinion, these and
other leukocytes could equally transport conventional infectious
agents bearing prions. The immunitary system could serve as
a reservoir where prions would be selected, silently, during the
incubation phase of TSE [1].
This possible multifactorial nature of prion-due diseases would
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Fig. 4 Generation of polymorphism in prions species. The different
conformations of infecting species (PrP*) are selected by PrPC, depending
on its capacity for conformational change. Thus, PrPC would undergo a
conformational change when challenged by some species but not others. Each
of the different conformations adopted by PrPC would constitute a strain of the
PrPC species (defined by its sequence)
explain why the incubation period of CJD ranges between a few
months and 10 years [38]. Certain bacteria might bear the genes
of the prions and/or prions, more or less suitable for causing
the conformational change of the PrPC of a given host, while others
would have to pass through a varying period of adaptation.
Induction of the structural change
Two distinct models for the conversion of PrPC to PrPSC have
been proposed. In the “seeding” model, the formation of PrPSC
is a nucleation-dependent polymerization process. In the
template-directed, or refolding, model, PrPSC could promote
conversion by catalyzing the rearrangement of a molecule of
PrPC, or of a partially destabilized intermediate, to the more
stable PrPSC conformation (reviewed in [18]).
In yeasts, in vitro conversion assays support the nucleation-
polymerization model [15, 23, 33]. However, this model could
be compatible with the template-directed model and both
mechanisms could be involved [18, 29]. In this sense, in the
case of tubulin polymerization, the polymerizing monomers
can assume the conformation of even heterologous seed
material, reflecting a “templating” behaviour [18].
We believe that this question could be explained within the
framework of our hypothesis. Thus, we propose that in the large
majority of cases, if not in all, the conversion of PrPC is mediated
by exogenous PrP*. In vivo, PrP* would be a mixture of
different strains. The different exogenous strains can be
distinguished by their ability to induce different conformational
changes in PrPC, generating the corresponding PrPC strains
(different conformations of the same sequence). Each of these
new strains would exhibit a different kind of behaviour,
characterized by its greater or lesser tendency to be infectious
( i.e., to induce new conformational changes in PrPC) or to form
only aggregates. Under certain conditions, at least part of the
PrP* could form aggregates.
As proposed, protein X could be a chaperone. Perhaps there
might be more than one chaperone; one of them might participate
in the conformational change process, whereas the other might
accumulate misfolded PrP (perhaps only the non-infectious type).
In this sense, we believe that the participation of chaperones could
be different in yeasts, where one is dealing with a physiological
process, from the situation in mammals, where one is dealing
with a pathological process. In mammals, transformed PrP could
aggregate with the help of a chaperone in a non-infectious,
protease-resistant form (PrPSC or PrPres) (Fig. 5).
The main genetic determinant of TSE lies in the fact that
if no PrP gene is present, there is no substrate to be changed.
Furthermore, certain mutations of PrP may favour infection by
certain prion strains.
In our hypothesis, the common element is the entry, in
greater or lesser amounts, and selection of an exogenous
infectious protein (PrP*) into a host cell, which then produces
the corresponding PrPC compatible with the conformational
change. The prion and/or its genes could enter the host by
“riding” conventional infectious agents.
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